Physician profile
Damian Green
NPI 1801002076
$18,191.79
in general payments reported to CMS, 2019-2025
11 companies · $494 in 2025
The $494 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,241 · 2020: $1,860 · 2021: $1,950 · 2022: $5,368 · 2024: $279 · 2025: $494.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $773.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $772.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $6,500.00 | 2019-2022 | |
| Celgene Corporation | $5,043.00 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $2,768.00 | 2022 | |
| Janssen Biotech, INC. | $1,994.87 | 2020-2025 | Carvykti |
| Seagen INC. | $1,248.03 | 2019 | |
| Janssen Scientific Affairs, LLC | $180.19 | 2025 | Darzalex, Tecvayli, Talvey |
| Astrazeneca Pharmaceuticals Lp | $159.81 | 2024-2025 | |
| Genzyme Corporation | $149.89 | 2024 | |
| Genetix Biotherapeutics INC | $118.54 | 2025 | Lyfgenia |
| Tempus Ai, INC | $29.46 | 2024 | Xt Cdx |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Damian Green listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.